New blood filter could ease heart drug dependence in shock patients
NCT ID NCT05027529
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding a special blood filter called CytoSorb to standard ECMO support helps people with cardiogenic shock (a severe form of heart failure). The filter aims to remove inflammatory substances from the blood. Researchers measured how much heart-support medication patients needed after 72 hours. The trial included 42 critically ill adults and compared those getting ECMO plus the filter to those getting ECMO alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CytoSorb device (a filter that removes inflammatory substances from the blood)
What this could lead to
If it works, this could point toward a way to reduce the need for strong heart medications in patients on ECMO for cardiogenic shock.
What could go wrong
This is a small, early-stage trial with only 42 patients, so results may not apply broadly. The device adds complexity and may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jena University Hospital, Department of Cardiology
Jena, Thuringia, 07747, Germany